PILA PHARMA AB (PILA) wishes to develop an oral anti-diabetic agent that effectively controls hyperglycemia and bodyweight gain in type 2 diabetes without increasing the risk of having cardiovascular disease.

The TRPV1 target (also called the “chili-receptor”) has been shown to have applications across pain and inflammatory diseases and is speculated to have a role in diabetes as well.

PILA PHARMA owns issued use-patents that give the exclusive right to treat diabetes and obesity with antagonists of the TRPV1 receptor.

The company has recently acquired a TRPV1 antagonist asset including the clinical ready and safe development candidate XEN-D0501 and plans to develop this molecule as a novel oral anti-diabetic agent via a fast-track, low-risk clinical development programme until clinical proof-of-concept followed by exit.